{"id":3860,"date":"2012-08-31T06:56:08","date_gmt":"2012-08-31T06:56:08","guid":{"rendered":"https:\/\/synlab.ee\/?p=3860"},"modified":"2012-08-31T06:56:08","modified_gmt":"2012-08-31T06:56:08","slug":"changes-in-molecular-diagnostics-of-quattromed-hti","status":"publish","type":"post","link":"https:\/\/synlab.ee\/en\/changes-in-molecular-diagnostics-of-quattromed-hti\/","title":{"rendered":"Changes in molecular diagnostics of Quattromed HTI"},"content":{"rendered":"

In order to maintain our innovative, science-based and customer-oriented approach in the fast developing world of laboratory medicine, Quattromed HTI has put a great emphasis on constantly developing our technical capabilities. Regarding this, we are delighted to announce a milestone in the work of molecular diagnostics department of Quattromed HTI. Starting from September 3rd<\/sup> 2012<\/strong> we will change the technical platform for majority of our molecular diagnostic analysis<\/strong>. As the outcome of long lasting collaboration and with the support from Enterprise Estonia (EAS) we have set up a new technical approach, which is unique in Estonia and rapidly gaining its popularity in the rest of the world, where after multiplying the genomic material of pathogens the final result will be assessed automatically on the\u00a0 hybridization platform Luminex xMap.<\/p>\n

 <\/p>\n

We would like to draw your attention to the benefits of our new platform:<\/p>\n

1)\u00a0\u00a0\u00a0 Handling time<\/strong> for several analyses will be decreased<\/strong> \u2013 the analyzing time for HPV (Human Papillomavirus) genotyping will be shortened by one business day.\u00a0 Chlamydia trachomatis<\/em> DNA and Neisseria gonorrhoeae<\/em> DNA analyses already include verifying analyses, allowing us to shorten the period of issuing positive results by one business day.<\/p>\n

2)\u00a0\u00a0\u00a0 Working process will be more automated<\/strong>, ensuring more effective and precise fitting to LIS, altogether assuring a higher quality for our clients.<\/p>\n

3)\u00a0\u00a0\u00a0 One sample<\/strong> material will be sufficient for several tests<\/strong>, making it possible to combine the diagnosing of different pathogens which cause similar symptoms into one diagnostic panel (we will soon send out\u00a0 more information about the new diagnostic panels in our next newsletter).<\/p>\n

4)\u00a0\u00a0\u00a0 Luminex xMap platform is very flexible<\/strong> and user friendly<\/strong>. Taking into consideration the feedback that we receive from our colleagues and partners we can add more tests and put together new diagnostic panels.<\/p>\n

5)\u00a0\u00a0\u00a0 More up-to-date<\/strong>: determing different pathogens we will be using these genome areas which are chosen according to the latest treatment- and diagnostic guidelines and scientific literature.<\/p>\n

6)\u00a0\u00a0\u00a0 We are adding new diagnostics<\/strong>:<\/p>\n